AbbVie

4AB.DE

Drug Manufacturers - General · Healthcare

Exchange

Frankfurt Stock Exchange

Winston Score

Winston is curious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Strong

Growth

Good

Cash Flow

Exceptional

Stability

Mixed

Valuation

Good

Dividends

Mixed

Track this stock — start free trial

Winston Score History

The full picture

AbbVie is a large American pharmaceutical company that discovers, makes, and sells prescription medicines. Its biggest product is Humira, a drug used to treat conditions like rheumatoid arthritis and Crohn's disease, which was once the best-selling drug in the world. AbbVie also sells cancer treatments, eye care medicines, and drugs for mental health conditions, selling mainly to hospitals, pharmacies, and insurance systems.

AbbVie earns money by selling its medicines to healthcare providers and distributors around the world, with most revenue coming from the United States. The company operates globally and generates roughly $55 billion in annual revenue, supported by a strong portfolio of patents and hard-to-replicate drug formulations. A key risk is that Humira has lost patent protection and now faces cheaper copycat competitors, so AbbVie's ability to grow depends heavily on newer drugs like Skyrizi and Rinvoq replacing that lost revenue over time.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+10.3% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+286.8% YoY

YoY Growth Rate

Strong earnings growth

Insider Activity

0.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

€6.9B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

AbbVie is a rare growth stock that's already generating positive cash flow while growing at 10%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

84.7%

Premium pricing power — 84.7% gross margin

Profit after running costs

Operating Margin

39.6%

Excellent — 39.6% operating margin

Return on the money invested

ROCE

10.4%

Below par — 10.4% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+10.3%

Steady sales growth (+10.3% YoY)

Profit growth

EPS YoY

+68.6%

Earnings growing fast (+68.6% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

308%

Turns 308% of profit into real cash

Spare cash per sale

FCF Margin

28.1%

Converts sales into free cash efficiently (28.1%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

7.17x

Adequate interest coverage (7.2x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

74.7x

no trend

Expensive — P/E 74.7

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+60.6

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (74.7 → 14.1)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

2.74%

no trend

Moderate income — 2.74% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

+0.4%

no trend

Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial